Evidence map›Paper›PMID 27073222›Full record

ArticleThe Journal of infectious diseases2016

T-Cell Activation Independently Associates With Immune Senescence in HIV-Infected Recipients of Long-term Antiretroviral Treatment.

Viviana Cobos Jiménez, Ferdinand W N M Wit, Maaike Joerink, Irma Maurer, Agnes M Harskamp, Judith Schouten, Maria Prins, Ester M M van Leeuwen, Thijs Booiman, Steven G Deeks and 3 more

Registry-linked trialAbstract read
In one paragraph

Article in The Journal of infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01466582 (Comorbidity and Aging With HIV, the agehIV Cohort Study), which is not on this map. Cited by 78 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01466582 active not recruitingnot on this map

Comorbidity and Aging With HIV, the agehIV Cohort Study

TypeobservationalSponsorAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Ran2010 to 2040Enrolled1,148ConditionsHIV-1-infection, Comorbidity, Ageing
3 · Its place in the literature

Who cites it

78 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Tenofovir, Interferon Pathways, and Mucosal Immunity: Implications for People Living With HIV.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026
    Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Viviana Cobos JiménezDepartment of Experimental Immunology Amsterdam Institute for Global Health and Development.
Ferdinand W N M WitDepartment of Global Health Division of Infectious Disease, Academic Medical Center of the University of Amsterdam Amsterdam Institute for Global Health and Development.
Maaike JoerinkDepartment of Experimental Immunology Amsterdam Institute for Global Health and Development.
Irma MaurerDepartment of Experimental Immunology.
Agnes M HarskampDepartment of Experimental Immunology.
Judith SchoutenDepartment of Global Health Division of Infectious Disease, Academic Medical Center of the University of Amsterdam Amsterdam Institute for Global Health and Development.
Maria PrinsPublic Health Service Amsterdam, The Netherlands.
Ester M M van LeeuwenDepartment of Experimental Immunology.
Thijs BooimanDepartment of Experimental Immunology Amsterdam Institute for Global Health and Development.
Steven G DeeksDepartment of Medicine, University of California-San Francisco.
Peter ReissDepartment of Global Health Division of Infectious Disease, Academic Medical Center of the University of Amsterdam Amsterdam Institute for Global Health and Development Stichting HIV Monitoring Foundation, Amsterdam-Zuidoost.
Neeltje A KootstraDepartment of Experimental Immunology.
AGEhIV Study Group

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
NIAID NIH HHS P30 AI027763
6 · The paper itself

Abstract

backgroundAging-associated noncommunicable comorbidities are more prevalent among human immunodeficiency virus type 1 (HIV)-infected individuals than among HIV-uninfected individuals. Residual HIV-related chronic immune activation and senescence may increase the risk of developing comorbidities.

methodsImmune phenotyping, thymic output, and telomere length were assessed in 94 HIV-infected individuals who were aged >45 years and receiving antiretroviral therapy (ART; cases) and 95 age-matched uninfected controls.

resultsCases had lower CD4(+) T-cell counts, higher CD8(+) T-cell counts, and increased levels of immune activation (ie, increased soluble CD14 [sCD14] level and increased percentages of CD38(+)HLA-DR(+) cells among both CD4(+) and CD8(+) T cells), regulatory T cells, and percentage of programmed cell death 1 (PD-1)-expressing cells among CD4(+) T cells. Immune senescence levels (ie, percentages of CD27(-)CD28(-) cells or CD57(+) cells) were comparable between cases and controls. Peripheral blood mononuclear cells from cases had shorter telomeres but increased single-joint T-cell receptor excision circle content and CD31(+) naive CD4(+) T cells. Although cytomegalovirus (CMV) antibody titers were higher in cases, CMV-specific T-cell responses were comparable between cases and controls. T-cell senescence in cases was independently associated with T-cell activation but not with CMV-specific immune responses.

conclusionsDespite long-term receipt of ART, HIV-infected adults had higher levels of immune activation, regulatory T cells, and PD-1-expressing CD4(+) cells and shorter telomeres. The increased soluble CD14 levels and percentage of CD38(+)HLA-DR(+) cells among CD4(+) T cells correlated with shorter telomeres and increased regulatory T-cell levels. This suggests that HIV influences immune function irreversibly, with several pathways that are persistently abnormal during effective ART. Therapies aimed at improving immune health during ART are needed.

Indexed as

Lymphocyte ActivationAgedAgingAnti-Retroviral AgentsCohort StudiesFemaleHIV InfectionsHumansImmunophenotypingLipopolysaccharide ReceptorsMaleMiddle AgedProgrammed Cell Death 1 ReceptorTelomereThymus GlandT-Lymphocytes, RegulatoryAnti-Retroviral AgentsLipopolysaccharide ReceptorsPDCD1 protein, humanProgrammed Cell Death 1 ReceptorARTHIVimmune activationsenescencetelomeresthymic output

Identifiers

PMID27073222
PMCPMC8445638

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.